East India Pharmaceutical Works Unlisted Share Price Today
ISIN INE254X01017.
East India Pharmaceutical Works (EIPW) is one of the oldest pharmaceutical companies in India, with a legacy dating back to 1936. The company is engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products, including tablets, syrups, drops, and Ayurvedic medicines, catering primarily to the domestic market. Its product portfolio spans analgesics, antibiotics, vitamins, hematinics, gastrointestinal medicines, and herbal formulations, with a focus on afforda…
East India Pharmaceutical Works
East India Pharmaceutical Works Unlisted Share Price Today
About Company
East India Pharmaceutical Works (EIPW) is one of the oldest pharmaceutical companies in India, with a legacy dating back to 1936. The company is engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products, including tablets, syrups, drops, and Ayurvedic medicines, catering primarily to the domestic market. Its product portfolio spans analgesics, antibiotics, vitamins, hematinics, gastrointestinal medicines, and herbal formulations, with a focus on affordable healthcare.
EIPW follows a manufacturing-led, formulation-driven operating model, supported by its facilities at Sarsuna and Durgapur. The company places strategic emphasis on cost-effective production, diversified product portfolio, and domestic distribution reach, rather than high-margin export-led growth. Its performance is closely linked to product demand, working capital management, pricing regulations, and operational efficiency, making scale and cost control critical to profitability.
Headquartered in Kolkata, EIPW primarily operates in the Indian market with a strong legacy presence. The company continues to focus on accessible healthcare solutions, compliance-driven manufacturing, and gradual capacity utilization improvements, positioning itself as a value-focused domestic pharmaceutical player.
EBITDA Margin declined from 7.6% (FY21) to 4.7% (FY25), indicating sustained pressure on operating profitability.
Revenue increased steadily from ₹172.7 Cr to ₹271.7 Cr (FY21–FY25), reflecting healthy top-line expansion.
PAT fluctuated significantly (₹3.14 Cr → ₹2.2 Cr) with sharp swings in EPS growth, indicating inconsistent bottom-line performance.
